Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunotherapy Combining Mimotopes Selected by Phage Display Plus Amphotericin B Is Effective for Treatment Against Visceral Leishmaniasis.
Soyer TG, Bandeira Câmara RS, Pereira IAG, Ramos FF, de Jesus MM, Ludolf F, de Paula Costa G, Lage DP, de Freitas CS, Vale DL, Pimenta BL, Martins VT, Galdino AS, Chávez-Fumagalli MA, Roatt BM, de Sousa Vieira Tavares G, Coelho EAF. Soyer TG, et al. Among authors: pimenta bl. Parasite Immunol. 2024 May;46(5):e13037. doi: 10.1111/pim.13037. Parasite Immunol. 2024. PMID: 38720446
The association between rLiHyp1 protein plus adjuvant and amphotericin B is an effective immunotherapy against visceral leishmaniasis in mice.
Lage DP, Martins VT, Vale DL, Freitas CS, Pimenta BL, Moreira GJL, Ramos FF, Pereira IAG, Bandeira RS, de Jesus MM, Ludolf F, Tavares GSV, Chávez-Fumagalli MA, Roatt BM, Christodoulides M, Coelho EAF. Lage DP, et al. Among authors: pimenta bl. Acta Trop. 2023 Oct;246:106986. doi: 10.1016/j.actatropica.2023.106986. Epub 2023 Jul 14. Acta Trop. 2023. PMID: 37453579
Immunization with recombinant LiHyp1 protein plus adjuvant is protective against tegumentary leishmaniasis.
Jesus MM, Lage DP, Vale DL, Freitas CS, Pimenta BL, Moreira GJL, Ramos FF, Pereira IAG, Bandeira RS, Ludolf F, Tavares GSV, Galdino AS, Duarte MC, Menezes-Souza D, Chávez-Fumagalli MA, Teixeira AL, Gonçalves DU, Roatt BM, Christodoulides M, Martins VT, Coelho EAF. Jesus MM, et al. Among authors: pimenta bl. Parasitol Res. 2023 Dec;122(12):2917-2931. doi: 10.1007/s00436-023-07981-6. Epub 2023 Sep 28. Parasitol Res. 2023. PMID: 37768367
New synthetic molecules incorporated into polymeric micelles used for treatment against visceral leishmaniasis.
Freitas CS, Pereira IAG, Lage DP, Vale DL, Pimenta BL, Soares NP, Santiago SS, Martins VT, Câmara RSB, Jesus MM, Tavares GSV, Ramos FF, Ludolf F, Magalhães LND, Oliveira FM, Duarte MC, Chávez-Fumagalli MA, Costa AV, Roatt BM, Teixeira RR, Coelho EAF. Freitas CS, et al. Among authors: pimenta bl. Cytokine. 2024 May;177:156543. doi: 10.1016/j.cyto.2024.156543. Epub 2024 Feb 18. Cytokine. 2024. PMID: 38373365
Treatment using vanillin-derived synthetic molecules incorporated into polymeric micelles is effective against infection caused by Leishmania amazonensis species.
Pereira IAG, Freitas CS, Câmara RSB, Jesus MM, Lage DP, Tavares GSV, Soyer TG, Ramos FF, Soares NP, Santiago SS, Martins VT, Vale DL, Pimenta BL, Ludolf F, Oliveira FM, Duarte MC, Chávez-Fumagalli MA, Costa AV, Gonçalves DU, Roatt BM, Teixeira RR, Coelho EAF. Pereira IAG, et al. Among authors: pimenta bl. Exp Parasitol. 2024 May;260:108743. doi: 10.1016/j.exppara.2024.108743. Epub 2024 Mar 19. Exp Parasitol. 2024. PMID: 38513973
Non-invasive urine-based ELISA using a recombinant Leishmania protein to diagnose tegumentary leishmaniasis.
Câmara RSB, Pereira IAG, Lage DP, Vale DL, Ludolf F, Cardoso MM, Freitas CS, Oliveira-da-Silva JA, Assis BPN, Chaves AT, Pimenta BL, Silva MGP, Tavares GSV, Galdino AS, Tupinambás U, Chávez-Fumagalli MA, Pascoal VPM, Eller MTC, Rocha MODC, Machado-de-Ávila RA, Gonçalves DU, Coelho EAF. Câmara RSB, et al. Among authors: pimenta bl. Acta Trop. 2024 Oct;258:107326. doi: 10.1016/j.actatropica.2024.107326. Epub 2024 Jul 17. Acta Trop. 2024. PMID: 39029609
Preclinical evaluation of immunogenicity and protective efficacy of a recombinant chimeric protein vaccine against visceral leishmaniasis.
Lage DP, Vale DL, Maia FAG, Martins VT, Silva MGP, Galvani NC, Cardoso MM, Moreira GJL, Sombrio EM, Freitas CS, Pimenta BL, Falcão KOM, Dias SSG, Bandeira RS, Pereira IAG, Tavares GSV, Teixeira AL, Chávez-Fumagalli MA, Roatt BM, Machado-de-Ávila RA, Coelho EAF. Lage DP, et al. Among authors: pimenta bl. Parasitology. 2024 Nov 28:1-13. doi: 10.1017/S0031182024001240. Online ahead of print. Parasitology. 2024. PMID: 39604215
Urine and serum-based ELISA using a recombinant protein and synthetic peptide for the diagnosis of tegumentary leishmaniasis.
Freitas CS, Câmara RSB, Lage DP, Vale DL, Silva AL, Pimenta BL, Ludolf F, Galvani NC, de Jesus MM, Assis BPN, Chaves AT, Tavares GSV, Tupinambás U, Chávez-Fumagalli MA, Pascoal VPM, Eller MTC, Rocha MODC, Christodoulides M, Machado-de-Ávila RA, Gonçalves DU, Pereira IAG, Coelho EAF. Freitas CS, et al. Among authors: pimenta bl. Diagn Microbiol Infect Dis. 2024 Nov 27;111(3):116631. doi: 10.1016/j.diagmicrobio.2024.116631. Online ahead of print. Diagn Microbiol Infect Dis. 2024. PMID: 39637680